Business
NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
VANCOUVER, BC - March 16, 2026 (NEWMEDIAWIRE) - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd., today announces that pursuant to its ongoing collabo...
About this update from Clearmind Medicine Inc.
[{"type":"text","content":"VANCOUVER, BC - March 16, 2026 (NEWMEDIAWIRE) - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd., today announces that pursuant to its ongoing collaboration with Clearmind Medicine Inc. ("Clearmind"), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).","length":530,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"The Newswire","className":"","disableSlideshowImg":false,"size":{"original":{"width":306,"height":100,"url":"https://media.zenfs.com/en/newsmediawire_165/2269f64d7031f03ade32bd8a89596e30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TWrmzc0evQlpD_3_bcaRBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/2269f64d7031f03ade32bd8a89596e30","width":306,"height":100}}},{"type":"text","content":"This innovative treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.","length":149,"tagName":"p"},{"type":"text","content":"The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled "Depressive Disorder (Depression)", published in August 2025 Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and other conventional options.","length":570,"tagName":"p"},{"type":"text","content":"About NeuroThera Labs Inc.","length":26,"tagName":"p"},{"type":"text","content":"NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.","length":246,"tagName":"p"},{"type":"text","content":"About Clearmind Medicine Inc.","length":29,"tagName":"p"},{"type":"...